Form 4: Solid Biosciences CFO Reports Equity Vesting, Tax Sale

Sentiment:

Insider Transaction Report 2 February 2026 8:18 PM

Solid Biosciences CFO Kevin Tan reported the vesting of performance and restricted stock units, alongside a tax-related sale of common stock.

Summary

Kevin Tan, CFO & Treasurer of Solid Biosciences Inc. (SLDB), reported several transactions related to his equity compensation.
On January 29, 2026, 56,646 Performance Stock Units (PSUs) vested into common stock, following the achievement of a pre-determined performance milestone.
Also on January 29, 2026, Mr. Tan was granted 187,000 Employee Stock Options with an exercise price of $6.60 and 93,500 Restricted Stock Units (RSUs).
On January 31, 2026, 33,075 Restricted Stock Units (RSUs) vested into common stock, originating from a grant on January 31, 2025.
On February 2, 2026, Mr. Tan sold 26,837 shares of common stock at a weighted average price of $6.4369 per share. This sale was non-discretionary and executed to cover withholding taxes associated with the vesting of previously granted PSUs, as per a Rule 10b5-1 plan adopted on August 15, 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting routine executive compensation events and a tax-related stock sale, which are standard for publicly traded companies.

Positives

Vesting of 56,646 Performance Stock Units (PSUs) indicates the achievement of a significant business objective or performance milestone by the company, as certified by the Board.
The grant of 187,000 Employee Stock Options and 93,500 Restricted Stock Units (RSUs) on January 29, 2026, provides ongoing incentives for the CFO, aligning his interests with long-term shareholder value.
The vesting of 33,075 Restricted Stock Units (RSUs) on January 31, 2026, reflects continued service and retention of a key executive.

Negatives

The sale of 26,837 shares of common stock, even for tax purposes, results in a reduction of the CFO's direct beneficial ownership in the company.

Future Outlook

The filing indicates future vesting schedules for granted employee stock options and restricted stock units, with options vesting over four years starting January 29, 2027, and RSUs vesting annually until January 29, 2029. Further performance milestones for PSUs are also anticipated.

Industry Context

StockSavvy.ai notes that routine insider transaction reports like this Form 4 are common for publicly traded companies, reflecting standard executive compensation practices involving equity awards. The vesting of performance-based units suggests the company is meeting internal operational or strategic goals, which is generally viewed positively within the biotech industry, where milestones are critical.

Related Party Transactions

Equity compensation awards (Performance Stock Units, Restricted Stock Units, and Employee Stock Options) granted to Kevin Tan, the CFO & Treasurer, are considered related party transactions.
The sale of common stock by Kevin Tan to cover withholding taxes related to vested equity awards is also a related party transaction.

Stakeholder Impact

Shareholders: The vesting of performance-based units could be seen as positive, indicating the achievement of company objectives. The grant of new equity awards aligns executive incentives with shareholder interests. The tax-related sale is a minor, non-discretionary reduction in insider ownership.
Employees: The equity compensation structure for the CFO may reflect broader compensation strategies within the company, potentially impacting employee morale and retention if similar structures are applied.

Next Steps

Continued vesting of the remaining 75% of the PSUs upon achievement of three additional independent performance milestones.
Vesting of 25% of the 187,000 Employee Stock Options on January 29, 2027, with monthly vesting thereafter until January 29, 2030.
Annual vesting of 25% of the 93,500 Restricted Stock Units on each anniversary of January 29, 2026, until January 29, 2029.
Annual vesting of the remaining 99,225 Restricted Stock Units (from the 2025 grant) on each anniversary of January 31, 2025, until January 31, 2028.

Key Dates

Date	Description
2024-06-11	Grant date of Performance Stock Units (PSUs) to Kevin Tan.
2024-08-15	Date Kevin Tan adopted the Rule 10b5-1 plan for automatic sale instructions to cover withholding taxes.
2025-01-31	Grant date of 132,300 Restricted Stock Units (RSUs) to Kevin Tan (referred to as '2025 Grant Date').
2026-01-29	Date the first Performance Milestone for PSUs was met, resulting in the vesting of 25% of the underlying shares. Also, the grant date for 187,000 Employee Stock Options and 93,500 Restricted Stock Units (referred to as '2026 Grant Date').
2026-01-31	Vesting date for 33,075 Restricted Stock Units from the 2025 grant.
2026-02-02	Date of common stock sale by Kevin Tan to cover withholding taxes.
2027-01-29	First anniversary of the 2026 Grant Date, when 25% of the 187,000 Employee Stock Options are scheduled to vest.
2028-01-31	Fourth anniversary of the 2025 Grant Date, marking the final vesting for the 132,300 RSUs granted on that date.
2029-01-29	Fourth anniversary of the 2026 Grant Date, marking the final vesting for the 93,500 RSUs granted on that date.
2030-01-29	Fourth anniversary of the 2026 Grant Date, marking the final vesting for the 187,000 Employee Stock Options granted on that date.
2036-01-29	Expiration date of the Employee Stock Options granted on January 29, 2026.

Keywords

Solid Biosciences, SLDB, Form 4, Insider Transaction, Executive Compensation, Stock Options, Restricted Stock Units, Performance Stock Units, Kevin Tan, Equity Vesting, Sell-to-Cover

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.